Related Experiment Videos
Resting T cells negatively regulate osteoclast generation from peripheral blood monocytes
K Shinoda1, E Sugiyama, H Taki
1First Department of Internal Medicine, Toyama Medical and Pharmaceutical University, Toyama 930-0194, Japan.
Bone
|October 14, 2003
Summary
Resting T cells inhibit human osteoclast generation through CD4+ T cell cytokines granulocyte-macrophage colony-stimulating factor (GM-CSF) and interferon-gamma (IFN-γ). Cyclosporine A (CsA) stimulates osteoclast formation by blocking these T cell cytokines, offering insights into immunosuppression-induced bone loss.
Area of Science:
- Immunology
- Bone Biology
- Cellular Regulation
Background:
- T cell involvement in osteoclastogenesis is suggested in murine models.
- The precise role of human T cells in regulating osteoclast generation remains unclear.
- Understanding T cell regulation of osteoclast formation is crucial for bone health.
Purpose of the Study:
- To investigate the effect of resting human T cells on osteoclast generation from monocytes.
- To elucidate the mechanisms by which T cells regulate osteoclastogenesis.
- To explore the impact of cyclosporine A (CsA) on T cell-mediated osteoclast regulation.
Main Methods:
- Co-culture of human peripheral blood mononuclear cells (PBMCs), isolated T cells, and monocytes.
- Assessment of osteoclast generation using tartrate-resistant acid phosphatase (TRAP) staining and pit assays.
- Analysis of cytokine production (GM-CSF, IFN-γ) and the effect of neutralizing antibodies and CsA.
Main Results:
- Resting T cells inhibited receptor activator of NF-kappaB ligand (RANKL)-induced osteoclast generation from monocytes.
- T cells produced granulocyte-macrophage colony-stimulating factor (GM-CSF) and interferon-gamma (IFN-γ), primarily via CD4+ T cells.
- Cyclosporine A (CsA) rescued T cell-mediated inhibition and suppressed GM-CSF and IFN-γ production.
Conclusions:
- Resting T cells, specifically CD4+ T cells, negatively regulate human osteoclast generation via GM-CSF and IFN-γ.
- CsA promotes osteoclastogenesis by inhibiting the production of these inhibitory T cell cytokines.
- Findings offer new therapeutic strategies for managing bone loss associated with immunosuppression.